Depomed launches Lazanda nasal spray for breakthrough pain in cancer patients
NEWARK, Calif. — Depomed has launched a new drug for breakthrough pain in cancer patients, the company said Monday.
The drug maker announced the launch of Lazanda (fentanyl) nasal spray, meant for treating adults who are taking opioid painkillers, but have become tolerant to them. The company also have launched a Signature Support Program designed to streamline patient access to the drug, including reimbursement and co-pay assistance. Other benefits of the program include prescription reminders and eligibility for one month’s supply for free.
"Breakthrough pain is very common among cancer patients and can be properly managed to reduce the number and severity of episodes and the interference of daily activities," University of Arizona anesthesiology professor Emil Annabi said. "Studies show that breakthrough pain is associated with poorer function and higher cost of care, which is why cancer patients need support services so they can focus on getting pain relief and not be troubled by reimbursement and access issues."
Accreditation Council for Pharmacy Education to work with francophone counterpart on pharmacy education standards
CHICAGO — The Accreditation Council for Pharmacy Education has established a memorandum of understanding with an organization of French-speaking pharmacy school deans and educators to cooperate and collaborate to advance the quality of pharmacy education around the world.
The ACPE announced the memorandum with the Conférence internationale des doyens de pharmacie d’expression française, or CIDPHARMEF, saying the two groups would engage in ongoing communication and information exchange regarding educational quality, policies and procedures and operational tools and resources. Leaders of both would observe site visits and study each other’s quality assurance systems and processes.
"Cooperation with other organizations working to improve pharmacy education is a priority in our actions and, in particular, with ACPE, with whom we intend to work together to improve and expand our actions in the field of pharmacy to offer our future pharmacists quality training tailored to the pharmacy field," CIDPHARMEF president Dolla Karam Sarkis said. "ACPE has developed quality standards that have been inspiring and very useful for CIDPHARMEF when developing its own quality guidelines."
CVS/pharmacy’s myWeekly Ad in the spotlight; what does it mean for vendors?
CVS/pharmacy’s SVP and chief marketing officer Rob Price was recently featured on Yahoo! Finance’s Big Data Download to talk about the launch of its new myWeekly Ad, which is a digital circular powered by its ExtraCare loyalty program.
This is important as it demonstrates that CVS/pharmacy continues to get major attention for the new program, and it further illustrates the push — major push — that the retailer is making on personalization.
It was indeed the topic of discussion when Drug Store News traveled to CVS Caremark’s headquarters in Woonsocket, R.I., a few months ago to talk about the company’s retail initiatives for a report in the Oct. 14 issue of the magazine. Now, CVS/pharmacy is hitting the airwaves to talk about the initiative.
The message for vendors is that there is no one size fits all any more. Vendors must recalibrate what success looks like. Personalization, segmentation and clustering means that a vendor can have better results in 1,000 stores today in the right markets with the right customers, than it could have in 7,000 stores sending out tons of product that never turns.
It also means that you have to have a firm view of who your customer is, and what the role for your product is in their lives.